2019年10月30日 · Our efforts have led to the discovery of AMG 510, which is, to our knowledge, the first KRAS (G12C) inhibitor in clinical development. In preclinical analyses, treatment with …

2019年12月10日 · Biopharmaceutical optimization of the resulting leads culminated in the identification of AMG 510, a highly potent, selective, and well-tolerated KRAS G12C inhibitor …

2021年6月25日 · The CodeBreaK 100 trial, funded by Amgen and NCI, is testing sotorasib (previously called AMG510) as a treatment for people with solid tumors that have KRAS …

Our efforts have led to the discovery of AMG 510, which is, to our knowledge, the first KRAS (G12C) inhibitor in clinical development. In preclinical analyses, treatment with AMG 510 led to …

2020年9月20日 · Sotorasib (AMG 510) is a small molecule that specifically and irreversibly inhibits KRAS G12C through a unique interaction with the P2 pocket (Fig. S1 in the Supplementary …

In preclinical tumor models, Sotorasib (AMG-510) rapidly and irreversibly binds to KRAS G12C, providing durable suppression of the mitogen-activated protein kinase (MAPK) signaling …

2020年1月9日 · Biopharmaceutical optimization of the resulting leads culminated in the identification of AMG 510, a highly potent, selective, and well-tolerated KRAS G12C inhibitor …

THOUSAND OAKS, Calif., May 29, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the CodeBreaK 100 clinical development program evaluating …

2023年9月14日 · AMG510 is the first medication of its kind to reach clinical testing and binds to mutated KRAS protein which “turns off” the signals it sends to trigger cell division and cancer …

Titled "The Clinical KRAS G12C Inhibitor AMG 510 Drives Anti-Tumor Immunity," the paper highlights novel structural insights that led to the discovery of AMG 510, the preclinical …